137 related articles for article (PubMed ID: 8141566)
1. Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase.
Gootz TD; McGuirk PR; Moynihan MS; Haskell SL
Antimicrob Agents Chemother; 1994 Jan; 38(1):130-3. PubMed ID: 8141566
[TBL] [Abstract][Full Text] [Related]
2. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential.
Elsea SH; McGuirk PR; Gootz TD; Moynihan M; Osheroff N
Antimicrob Agents Chemother; 1993 Oct; 37(10):2179-86. PubMed ID: 8257142
[TBL] [Abstract][Full Text] [Related]
3. Stereo (C7)-dependent topoisomerase II inhibition and tumor growth suppression by a new quinolone, BO-2367.
Yoshinari T; Mano E; Arakawa H; Kurama M; Iguchi T; Nakagawa S; Tanaka N; Okura A
Jpn J Cancer Res; 1993 Jul; 84(7):800-6. PubMed ID: 8396568
[TBL] [Abstract][Full Text] [Related]
4. Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
Wentland MP; Lesher GY; Reuman M; Gruett MD; Singh B; Aldous SC; Dorff PH; Rake JB; Coughlin SA
J Med Chem; 1993 Sep; 36(19):2801-9. PubMed ID: 8410993
[TBL] [Abstract][Full Text] [Related]
5. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
6. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
[TBL] [Abstract][Full Text] [Related]
7. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
Kitamura A; Hoshino K; Kimura Y; Hayakawa I; Sato K
Antimicrob Agents Chemother; 1995 Jul; 39(7):1467-71. PubMed ID: 7492087
[TBL] [Abstract][Full Text] [Related]
8. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Osheroff N
Antimicrob Agents Chemother; 1992 Apr; 36(4):751-6. PubMed ID: 1323952
[TBL] [Abstract][Full Text] [Related]
9. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.
Miyamoto T; Matsumoto J; Chiba K; Egawa H; Shibamori K; Minamida A; Nishimura Y; Okada H; Kataoka M; Fujita M
J Med Chem; 1990 Jun; 33(6):1645-56. PubMed ID: 2342057
[TBL] [Abstract][Full Text] [Related]
11. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
12. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
13. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
14. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
15. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
[TBL] [Abstract][Full Text] [Related]
16. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.
Barrett JF; Gootz TD; McGuirk PR; Farrell CA; Sokolowski SA
Antimicrob Agents Chemother; 1989 Oct; 33(10):1697-703. PubMed ID: 2556075
[TBL] [Abstract][Full Text] [Related]
17. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
Bromberg KD; Burgin AB; Osheroff N
Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
[TBL] [Abstract][Full Text] [Related]
18. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.
Dong J; Walker J; Nitiss JL
J Biol Chem; 2000 Mar; 275(11):7980-7. PubMed ID: 10713116
[TBL] [Abstract][Full Text] [Related]
19. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structure-activity relationship of Q-35 analogs.
Ito T; Kojima K; Koizumi K; Nagano H; Nishino T
Biol Pharm Bull; 1994 Jul; 17(7):927-30. PubMed ID: 8000379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
